Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: Prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours

Thrombosis and Haemostasis

Volumn 96, Issue 2, 2006, Pages 202-209

  Gyöngyösi, Mariann ^a   Strehblow, Christoph ^a   Sperker, Wolfgang ^a   Hevesi, Akos ^b   Garamvölgyi, Rita ^b   Petrási, Zsolt ^b   Pavo, Noemi ^a   Ferdinandy, Péter ^c   Csonka, Csaba ^c   Csont, Tamás ^c   Sylvén, Christer ^d   Declerck, Paul J ^e   Pavo Jr , Imre ^a   Wojta, Johann ^a   Glogar, Dietmar ^a   Huber, Kurt ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b SZENT ISTVÁN UNIVERSITY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Wilhelminenhospital   (Austria)

Author keywords

Coronary circulation; Platelets; Stents; Thrombosis; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEATH; DRUG ELUTING STENT; FOLLOW UP; IN VIVO STUDY; IN-STENT RESTENOSIS; MULTIVARIATE ANALYSIS; NONHUMAN; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGICAL RISK; SURVIVAL RATE; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME; THROMBOGENICITY;

ANGIOGRAPHY; ANIMALS; BLOOD PLATELETS; CORONARY RESTENOSIS; CORONARY VESSELS; FIBRINOLYSIS; MICROSCOPY, ELECTRON, SCANNING; PLATELET ACTIVATION; STENTS; SWINE; THROMBIN; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS;

EID: 33747099225     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-03-0178     Document Type: Article

References (41)

1. Regar E, Lemos PA, Saia F, et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol 2004; 93: 1271-5.
2. Alfonso F, Suarez A, Angiolillo DJ, et al. Findings of intravascular ultrasound during acute stent thrombosis. Heart 2004; 90: 1455-9.
3. Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents. Circulation 2004; 109: 2732-6.
4. Scheller B, Hennen B, Pohl A, et al. Acute and sub-acute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J 2001; 5: 385-91.
5. Gupta V, Aravamuthan BR, Baskerville S, et al. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, real world registry. J Invasive Cardiol 2004; 16: 304-10.
6. Colombo A, Drzewiecki J, Banning A, et al. for the TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-94.
7. Honda Y, Fitzgerald PJ. Stent thrombosis. An issue revisited in a changing world. Circulation 2003; 108: 2-5.
8. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-30.
9. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2.
10. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysis. J Am Coll Cardiol 2005; 45: 941-6.
11. Biondi-Zoccai GG, Sangiorgi GM, Chieffo A, et al., RECIPE (Real-world Eluting-stent Comparative Italian retrosPective Evaluation) Study Investigators. Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. Am J Cardiol 2005; 95: 1466-8.
12. Tolleson TR, Newby LK, Harrington RA, et al., SYMPHONY and the 2nd SYMPHONY Investigators. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003; 92: 330-3.
13. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: are human and animal studies comparable? Heart 2003; 89: 133-8.
14. Virmani R, Farb A, Guagliumi G, et al. Drug-eluting stents: caution and concerns for long-term outcome. Cor Art Dis 2004; 15: 313-8.
15. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-74.
16. Schwartz RS, Edelman ER, for the Consensus Committee. Drug-eluting stents in preclinical studies. Recommended evaluation from a consensus group. Circulation 2002; 106: 1867-73.
17. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents still important, still much to learn. J Am Coll Cardiol 2004; 44: 1373-85.
18. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26: 1180-7.
19. Saadi BS, Holzknecht RA, Patte C, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-14.
20. Leng HM, Brouwers E, Knockaert I, et al. Immunoassays for the quantitation of porcine PAI-1 antigen and activity in biological fluid samples. Thromb Haemost 2000; 84: 1082-6.
21. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost 2004; 91: 425-37.
22. Scharf RE, Tomer A, Marzec UM, et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12: 1475-8.
23. Neumann FJ, Ott I, Gawaz M, et al. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-24.
24. Gawaz M, Neumann FJ, Ott I, et al. Platelet activation and coronary stent implantation. Effect of anti-thrombotic therapy. Circulation 1996; 94: 279-85.
25. Serruys PW, Strauss BH, van Beusekom HM, et al. Stenting of coronary arteries: has a modern Pandora's box been opened? J Am Coll Cardiol 1991; 17: 143B-54B.
26. Chia S, Megson IL, Ludlam CA, et al. Preserved endothelial vasomotion and fibrinolytic function in patients with acute stent thrombosis or in-stent restenosis. Thromb Res 2003; 111: 343-9.
27. Spronk HMH, van der Voort D, ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2004; 2: 12.
28. Palmerini T, Nedelman MA, Scudder LE, et al. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates. J Am Coll Cardiol 2002; 40: 360-6.
29. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocytc-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001; 142: 790-821.
30. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-8.
31. Steiner S, Seidinger D, Huber K, et al. Effect of glycoprotein IIb/III antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003; 23: 1697-702.
32. Sims PJ, Faioni EM, Wiedmer T, et al. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothombinase activity. J Biol Chemistry 1988; 263: 18205-12.
33. Stampfuss JJ, Censarek P, Fischer JW, et al. Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. Arterioscler Thromb Vasc Biol. 2006; 26: 34-7.
34. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
35. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque. J Am Coll Cardiol 2005; 46: 37-54.
36. Huber K. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis 2001; 11: 195-202.
37. Jeong MH, Owen WG, Staab ME, et al. Porcine model of stent thrombosis: platelets are the primary component of acute stent closure. Cathet Cardiovasc Diagn 1996; 38: 38-43.
38. Rukshin V, Azarbal B, Finkelstein A, et al. Effects of GP IIb/IIIa receptor inhibitor tirofiban (Aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis. J Cardiovasc Pharmacol TM 2003; 41: 615-24.
39. Cutlip DE. Stent thrombosis: historical perspectives and current trends. J Thromb Thrombolysis 2000; 10: 89-101.
40. Gyöngyösi M, Domanovits H, Benzer W, et al., ReoPro-BRIDGING Study Group. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004; 25: 2125-33.
41. Munster AM, Olsen AK, Bladbjerg EM. Usefulness of human coagulation and fibrinolysis assays in domestic pigs. Comp Med 2002; 52: 39-43.